At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Travoprost 0.004% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Travoprost Five Day Posology Study
In Brief
A Phase 2 clinical trial evaluating Travoprost 0.004%, Travoprost Vehicle, and 1 other intervention for Open-angle Glaucoma (OAG) and Ocular Hypertension. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen-angle Glaucoma (OAG), Ocular Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
Primary CompletionMay 2010
First PostedMay 2010
TodayJul 2026
First PostedMay 3, 2010
Enrollment StartApr 1, 2010
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.2 years ago
Interventions
Travoprost 0.004%drug
1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
Travoprost Vehicledrug
1 drop in each eye 8 times daily for 5 days
Travoprost (Groups A, B and C)drug
1 drop in each eye 8 times daily for 5 days